How to use charts when trading cfds and binary optionslevel 24
There is also no evidence to support the practice of extending anti-CDI therapy for the duration of therapy if the patient is also on a non-CDI antibiotic.
On the basis of two RCTs with oral vancomycin, the FDA granted approval for fidaxomicin in May 2011 (53,54). In both published phase III trials, fidaxomicin demonstrated non-inferiority to vancomycin in the modified intention-to-treat and the per-protocol analyses for clinical response at the end of therapy and at 25 days post therapy.
Further post-hoc analyses suggested that fidaxomicin is superior to vancomycin as there were fewer recurrences at 25 days after therapy.